Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence

被引:9
|
作者
Rajesh, V [1 ]
Augustine, Jolsana [1 ]
Divya, R. [1 ]
Cleetus, Melcy [1 ]
机构
[1] Rajagiri Hosp, Dept Pulm Med, Kochi, Kerala, India
关键词
FIXED-DOSE COMBINATION; ADULT PATIENTS; DRY-POWDER; RELATIVE BIOAVAILABILITY; OPEN-LABEL; PROPIONATE; ONSET; BUDESONIDE/FORMOTEROL; SALBUTAMOL; ADOLESCENT;
D O I
10.1155/2020/8631316
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control. A combination of the two agents in a single inhaler is beneficial with regard to ease of administration and patient compliance. Various ICS-LABA formulations are available across various countries in the world, one among them being formoterol-fluticasone. Both formoterol and fluticasone have pharmacologic peculiarities which places the combination in a uniquely advantageous position when it comes to asthma therapy. The present review focuses on some of the, hitherto, less explored aspects of this combination inhaler such as real-world efficacy, impact on budget allocation, results of switch-over therapy, and potential to improve adherence to asthma treatment. It also provides practical recommendations on positioning it in real-world asthma management.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] The Relationship Between Real-World Inhaled Corticosteroid Adherence and Asthma Outcomes: A Multilevel Approach
    Vervloet, Marcia
    van Dijk, Liset
    Spreeuwenberg, Peter
    Price, David
    Chisholm, Alison
    Van Ganse, Eric
    Pinnock, Hilary
    Rand, Cynthia S.
    Eakin, Michelle N.
    Schermer, Tjard
    Souverein, Patrick C.
    Dima, Alexandra L.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (02): : 626 - 634
  • [22] Real-World Impact of Adherence to Inhaled Corticosteroid/Long-Acting Beta-Agonists on Asthma Outcomes in the US
    Averell, C. M.
    Laliberte, F.
    Germain, G.
    MacKnight, S. D.
    Slade, D. J.
    Duh, M.
    Guisinger, A.
    Rousculp, M. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [23] Real-World Impact of Nonclinical Inhaler Regimen Switches on Asthma or COPD: A Systematic Review
    Usmani, Omar S.
    Bosnic-Anticevich, Sinthia
    Dekhuijzen, Richard
    Lavorini, Federico
    Bell, John
    Stjepanovic, Neda
    Swift, Stephanie L.
    Roche, Nicolas
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (10): : 2624 - 2637
  • [24] Exacerbations and Real-world Outcomes (EROS) Among Patients With COPD Receiving Single Inhaler Triple Therapy of Budesonide/glycopyrrolate/formoterol Fumarate
    Pollack, M.
    Tkacz, J. P.
    Schinkel, J.
    Lewing, B.
    Agatep, B.
    Swisher, S.
    Patel, S.
    Edwards, D.
    Touchette, D.
    Portillo, E.
    Feigler, N.
    Strange, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [25] Impact of Extrafine Formulation Single-inhaler Triple Therapy on Asthma Control and HRQoL After Three Months: TriMaximize - A Real-world View in Asthma Therapy from Austria
    Sator, L.
    Reisinger, M.
    Voves, R. V.
    Nevels, R.
    Hoermannstorfer-Fessl, K.
    Keckeis, A.
    Tiefenbacher, F.
    Ambrosch, G.
    Wuertz, M.
    Feizelmeier, H.
    Petrovic, M.
    Pohl, W.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 (19-20) : 563 - 564
  • [26] Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma
    Scicchitano, R
    Aalbers, R
    Ukena, D
    Manjra, A
    Fouquert, L
    Centanni, S
    Boulet, LP
    Naya, IP
    Hultquist, C
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (09) : 1403 - 1418
  • [27] Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real-world effectiveness and economic assessment
    Yu, Yuncui
    Cao, Wang
    Xiao, Yue
    Li, Ang
    Huang, Huijie
    Liu, Kejun
    Hu, Lihua
    Hou, Xiaoling
    Xiang, Li
    Wang, Xiaoling
    PEDIATRIC PULMONOLOGY, 2023, 58 (12) : 3406 - 3415
  • [28] Budesonide/Formoterol Maintenance and Reliever Therapy in Childhood Asthma: Real-World Effectiveness and Economic Assessment
    Lomonaco, Clarissa
    Dunn, Clinton
    PEDIATRICS, 2024, 154 : S50 - S50
  • [29] Fixed-dose combination fluticasone/formoterol for asthma treatment in a real-world setting: meta-analysis of exacerbation rates and asthma control
    Papi, Alberto
    Qasuri, Murtaza
    Chung, Ernestine
    Abdelbaset, Mohamed
    Moussa, Mohamed Aly
    Backer, Vibeke
    Schmidt, Olaf
    Usmani, Omar
    EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2023, 10 (01):
  • [30] Impact of extrafine single-inhaler triple therapy on treatment adherence after 6 months of treatment in asthmatics: a real-world view from Germany
    Trinkmann, Autoren F.
    Akyildiz, B.
    Grickschat, V
    Borucki, T.
    Gessner, C.
    PNEUMOLOGIE, 2023, 77 : S35 - S36